SplitKits for trypsin-free cell harvesting
Vegetable-based system offers gentler, more efficient and contamination-free dissociation
Developed using a vegetable-based component rather than trypsin, SplitKits avoid any risk of contamination with either animal or human viruses or bacteria, and are suitable for a variety of cell culture systems.
Independent studies conducted in both research and biopharmaceutical laboratories have shown that SplitKits also encourage faster cell dissociation than trypsin. Greater control of the dissociation process produces homogeneous cell suspensions with minimal batch-to-batch variation, the company says.
According to Sera, the gentle action of the SplitKits vegetable-based enzyme gives higher cell yields and better cell growth recovery following detachment. In addition, surface epitopes and cell membranes remain unaltered and fully functional, making the kits suitable for use in flow cytometry.
‘Drawing on 30 years of experience in cell culture, we have developed SplitKits to offer a significantly improved alternative to trypsin,’ said Jenny Murray, Sera Lab’s managing director. ‘For use in both laboratory cell culture and biopharmaceutical manufacturing, the increasing regulation of the use of animal-based components in the biopharmaceutical manufacturing environment means that SplitKits also offer the industry a potentially safer, more compliant system for cell culture.’
Each SplitKit comprises a vegetable-based enzymatic reagent (SplitCells), AntiSplitCells and a SplitCells buffer. There are three formats in the SplitKits range, each being optimised for use with specific cell types: SplitKit Strong, for strongly adherent and bioreactor-cultured cells; SplitKit Moderate for moderately adherent cells; and SplitKit Mild for mildly adherent cells.
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Semaglutide patent cliff: pharma industry braces for impact
Read moreWith the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Trending Articles
-
You need to be a subscriber to read this article.
Click here to find out more. -
You need to be a subscriber to read this article.
Click here to find out more.
Upcoming event
You may also like
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Analysis
Semaglutide patent cliff: pharma industry braces for impact
With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Manufacturing
LabVantage Solutions introduces LabVantage CORTEX, advancing its LIMS platform for AI-driven laboratory operations
Next-Generation Platform Extends LIMS with Agentic AI and Cloud-Native Automation to Improve Efficiency, Reduce Errors and Gain Deeper Insight from Data. Learn More from LabVantage Leadership at Pittcon 2026
Manufacturing
Schütz to build automated IBC production facility at BASF's Ludwigshafen headquarters
Packaging specialist Schütz has signed an agreement with BASF to construct a highly automated intermediate bulk container manufacturing and storage facility directly adjacent to the chemical giant's main plant in Ludwigshafen, enabling round-the-clock just-in-time delivery
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
LGM Pharma announces $9 million investment into Colorado and Texas manufacturing facilities
The investment marks the second phase of the the company's expansion, funding facility upgrades to increase capacity for suppository, semi-solid and oral solid dose and differentiating LGM in the US CDMO market, says CEO Prasad Raje, speaking exclusively to Manufacturing Chemist
Manufacturing
SGD Pharma partners with Prince Sterilisation Services for pharmaceutical glass packaging
The pair have already launched the My Sterinity Nasal platform, a new, versatile sterile vial range within SGD Pharma's My Sterinity RTU platform, using the company's U-Save Type I vials, which are designed to support the growing segment of high-value nasal drug delivery